Compare Rush Street Interactive Inc (RSI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs TG Therapeutics Inc — how do they compare? Rush Street Interactive Inc trades at $33.46 (market cap $3.55B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 2.3× Rush Street Interactive Inc's market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| RSI | TGTX | |
|---|---|---|
Market Cap | $3.55B | $8.26B |
Sector | Technology | Health |
52-Week High | $34.52 | $59.06 |
52-Week Low | $14.55 | $26.39 |
Enterprise Value | $3.23B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rush Street Interactive (RSI) trades at $34.52, up 6.22% in 24 hours, with strong bullish momentum from technical indicators and recent earnings beats. The stock shows robust revenue growth, reaching $1.13B in 2025, and maintains a 76.92% buy rating from analysts. Positive sentiment is fueled by expansion news, such as the BetRivers launch in Alberta (GlobeNewsWire, 2026-07-13).
Outlook remains positive with earnings growth as a key catalyst, though high valuation multiples (P/E 101.53) and overbought RSI levels pose risks. The consensus price target of $31.11 suggests potential downside, but institutional bullishness and operational cash flow strength support long-term upside if execution continues.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
